# US 2004/0034011 A1 · Derivatives of naphthalene with comt inhibiting activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0034011 A1
- Document ID: US20040034011A1
- Status: Published application
- Kind: A1
- Application number: 10/380,286
- Filed: 2003-07-09
- Published: 2004-02-19
- Earliest claimed: 2000-09-15
- Assignees: Orion Corporation
- Inventors: Reijo Bäckström; Jarmo Pystynen; Timo Lotta; Martti Ovaska; Jyrki Taskinen
- Web page: https://patentgrep.com/patent/US20040034011A1

## CPC

- C07D 207/452: with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
- A61P 25/16: Anti-Parkinson drugs
- C07C 45/00: Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C 45/30: with halogen containing compounds, e.g. hypohalogenation
- C07C 45/46: Friedel-Crafts reactions
- C07C 45/565: {by reaction with hexamethylene-tetramine}
- C07C 45/673: {by change of size of the carbon skeleton}
- C07C 47/57: polycyclic
- C07C 47/575: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 49/83: polycyclic
- C07C 49/84: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 65/11: with carboxyl groups on a condensed ring system containing two rings
- C07C 205/25: having nitro groups bound to carbon atoms of six-membered aromatic rings being part of a condensed ring system
- C07C 205/37: the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
- C07C 205/43: to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C 205/45: the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
- C07C 205/59: the carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C 245/10: with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems
- C07C 255/53: containing cyano groups and hydroxy groups bound to the carbon skeleton
- C07C 311/29: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07D 215/20: Oxygen atoms
- C07D 217/10: Quaternary compounds
- C07D 295/192: from aromatic carboxylic acids
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Compounds of formula (I′), wherein A, R1 to R3 and t are as defined in the disclosure, exhibit COMT enzyme inhibiting activity so that they are useful as COMT inhibitors.

## Claims

### Claim 1

A compound of formula I,
12
wherein the two OH— substituents in the phenyl moiety are in a position ortho to one another and R1 in a position ortho to one of the hydroxy groups;
and wherein
“A” is a fused ring moiety selected from benzo ring and a 6-membered heteroaromatic ring which contains one or two N heteroatoms;
t is 1, 2, 3 or 4;
R1 is NO2, CN, CHO or CF3; and
each R2 is selected independently from OH, halogen, NO2, SH, NH2, (C1-C6)alkyl, (C2-C6)alkenyl, (C1-C6)alkoxy, OH—(C1-C6)alkyl, NH2—(C1-C6)alkyl, halo-(C1-C6)alkyl, mono- or di(C1-C6)alkylamino, SO2R4, (C1-C20)alkyl-CO—, halo-(C1-C6)alkyl-CO—, phenyl-N═N— optionally substituted with one to three substituents R6, —(Y)n—(B)m—COOH and —(Y)n—(B)m—R5;
R3 is H, NO2, CN, CHO, halogen, CF3 or CH3; and
R4 is (C1-C6)alkyl, NH2, OH or mono- or di(C1-C6)alkylamino;
m is 0 or 1;
n is O or 1;
Y is —CO— or —CHOH—;
B is (C1-C6)alkylene or (C2-C6)alkenylene;
R5 is phenyl, naphthyl, (C3-C7)cycloalkyl or 5- to 10-membered heterocyclyl with one to four heteroatoms each selected independently from N, O and S, wherein the said phenyl, naphthyl, (C3-C7)cycloalkyl or 5- to 10-membered heterocyclyl is optionally substituted with one to five substituents R6,
or R5 is
13
each R6 is selected independently from OH, halogen, COOH, 5-tetrazolyl, NO2, SH, NH2, CN, CHO, ═O, (C1-C6)alkyl, (C1-C6)alkoxy, halo-(C1-C6)alkyl, mono- or di(C1-C6)alkylamino, CO—(C1-C6)alkyl, CO—NH2, mono- or di(C1-C6)alkylamino-CO—, NHOH, CONHOH or SO2R4;
or pharmaceutically acceptable salts or pharmaceutically acceptable esters thereof.

### Claim 2 (depends on 1)

A compound of claim 1, which is a compound of formula Ia,
14
wherein the two OH— substituents are in a position ortho to one another and R1 in a position ortho to one of the hydroxy groups; and R1 to R3 and t are as defined in claim 1.

### Claim 3 (depends on 1)

A compound of claim 1, which is a compound of formula Iaa
15
wherein R1 to R3 and t are as defined in claim 1.

### Claim 4 (depends on 1)

A compound of claim 1, which is a compound of formula Ib or Ic,
16
wherein R1 to R3 and t are as defined in claim 1.

### Claim 5 (depends on 1, 2, 3, 4)

A compound according to any one of claims 1 to 4, wherein R1 is NO2, CHO or CN.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A compound according to any one of claims 1 to 5, wherein R1 is NO2.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A compound according to any one of claims 1 to 6, wherein R3 is H.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A compound according to any one of claims 1 to 7, wherein t is 1 or 2 and each R2 is selected independently from OH, NH2, halogen, NO2, SO2R4, (C1-C6)alkyl, NH2—(C1-C6)alkyl, (C1-C20)alkyl-CO—, halo-(C1-C6)alkyl-CO—, phenyl-N═N—, wherein phenyl is optionally substituted with one to three substituent(s) R6, —(Y)n—(B)m—COOH or —(Y)n—(B)m—R5.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A compound according to any one of claims 1 to 8, wherein R2 is phenyl-N═N—, wherein phenyl is optionally substituted with one or two substituent(s) R6, —(Y)n—(B)m—COOH or —(Y)n—(B)m—R5, wherein n is 0 or 1 and Y is CO; m is 0 or 1 and B is (C1-C6)alkylene.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A compound according to any one of claims 1 to 9, wherein R5 is phenyl optionally substituted with one or two substituent(s) R6 selected independently from OH, halogen, (C1-C6)alkyl, (C1-C6)alkoxy, COOH and tetrazolyl; or R5 is tetrazol-5-yl, piperidin-1-yl, piperazin-1-yl, pyrrol-1-yl, pyrrolin-1-yl or pyrrolidin-1-yl, each optionally substituted with one or two substituent(s) R6 selected independently from (C1-C6)alkyl, (C1-C6)alkoxy or ═O.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A compound according to any one of claims 1 to 10, wherein or R5 is phenyl optionally substituted with one or two R6, or R5 is tetrazol-5-yl, 4-(C1-C6)alkyl-piperazin-1-yl or pyrrole-2,5-dion-1-yl.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A compound according to any one of claims 1 to 11, wherein R5 is tetrazol-5-yl or phenyl which is optionally substituted with one or two COOH or tetrazolyl.

### Claim 13

Use of a compound of formula I′:
17
wherein the two OH— substituents in the phenyl moiety are in a position ortho to one another and R1 is in a position ortho to one of the hydroxy groups;
and wherein
“A” is a fused ring moiety selected from benzo ring and a 6-membered heteroaromatic ring which contains one or two N heteroatoms;
R1 is NO2, CN, CHO, CF3 or (C1-C6)alkyl-CO—;
t is 0, 1, 2, 3 or 4;
each R2 is selected independently from OH, halogen, NO2, SH, NH2, (C1-C6)alkyl, (C2-C6)alkenyl, (C1-C6)alkoxy, OH—(C1-C6)alkyl, NH2—(C1-C6)alkyl, halo-(C1-C6)alkyl, mono- or di(C1-C6)alkylamino, SO2R4, (C1-C20)alkyl-CO—, halo-(C1-C6)alkyl-CO—, phenyl-N═N— optionally substituted with one to three substituents R6, —(Y)n—(B)m—COOH and —(Y)n—(B)m—R5;
R3 is H, NO2, CN, CHO, halogen, CF3 or (C1-C6)alkyl; and
R4 is (C1-C6)alkyl, NH2, OH or mono- or di(C1-C6)alkylamino;
m is 0 or 1;
n is 0 or 1;
Y is —CO— or —CHOH—;
B is (C1-C6)alkylene or (C2-C6)alkenylene;
R5 is phenyl, naphthyl, (C3-C7)cycloalkyl or 5- to 10-membered heterocyclyl with one to four heteroatoms each selected independently from N, O and S, wherein the said phenyl, naphthyl, (C3-C7)cycloalkyl or 5- to 10-membered heterocyclyl is optionally substituted with one to five substituents R6,
or R5 is
18
each R6 is selected independently from OH, halogen, COOH, 5-tetrazolyl, NO2, SH, NH2, CN, CHO, ═O, (C1-C6)alkyl, (C1-C6)alkoxy, halo-(C1-C6)alkyl, mono- or di(C1-C6)alkylamino, CO—(C1-C6)alkyl, CO—NH2, mono- or di(C1-C6)alkylamino-CO—, NHOH, CONHOH or SO2R4;
or pharmaceutically acceptable salts or pharmaceutically acceptable esters thereof, for the manufacture of a medicament as a COMT inhibiting agent.

### Claim 14 (depends on 13)

A pharmaceutical composition which comprises as an active agent a compound of formula I′
19
wherein the two OH— substituents in the phenyl moiety are in a position ortho to one another and R1 in a position ortho to one of the hydroxy groups; and
wherein A, R1 to R3 and t are as defined in claim 13; and optionally a pharmaceutically acceptable excipient.

### Claim 15 (depends on 13)

A method for the treatment of diseases or conditions where inhibitors of COMT enzyme are indicated to be useful, said method comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I′,
20
wherein the two OH— substituents in the phenyl moiety are in a position ortho to one another and R1 in a position ortho to one of the hydroxy groups; and
wherein A, R1 to R3 and t are as defined in claim 13.

### Claim 16 (depends on 13, 14, 15)

A use according to claim 13, a pharmaceutical composition according to claim 14 or a method according to claim 15, wherein the two hydroxy substituents in the phenyl moiety of a compound of formula I′ are in 2- and 3-positions (according to the numbering depicted in the description).

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15)

A use according to claim 13, a pharmaceutical composition according to claim 14 or a method according to claim 15, wherein a compound of formula I′ is a compound of formula I as defined in any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and/or 12.
